WASHINGTON — The Food and Drug Administration doesn’t have enough funding or staff to properly regulate pharmaceutical compounders, a top agency official said Friday, describing inspections that turned up “stuff floating around” in supposedly sterile shipments.

The program doesn’t “have adequate core staffing,” said Janet Woodcock, director of the Center for Drug Evaluation and Research, on Friday, adding that it’s one of the center’s programs that is “suffering the most.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I am a retired health care professional and I remain very interested in the
    areas of prescrip drug development and pricing and need for tighter regs
    over pharm development and physician scripts for meds not specifically
    approved for treatment of certain diagnoses. Impurities critical !

  • The FDA has utterly failed in it’s mission to protect public health. They chose to ignore this problem, even after all of those patents were injected with fungus tainted steroids. When Industry insiders decide where the regulations should be removed, while Congress under-funds necessary services, they are unable to function in the way they were intended to. This is what happens when science and facts are ignored to increase profitability.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy